---
title: "JAFRON released its first-quarter performance, with a net profit attributable to the parent company of 189 million yuan, a year-on-year decrease of 33.71%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236064125.md"
description: "According to the Zhitong Finance APP, JAFRON released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 548 million yuan, a year-on-year decrease of 26.40%. The net profit attributable to shareholders of the listed company was 189 million yuan, a year-on-year decrease of 33.71%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 184 million yuan, a year-on-year decrease of 32.15%"
datetime: "2025-04-15T13:04:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236064125.md)
  - [en](https://longbridge.com/en/news/236064125.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236064125.md)
generator: "portal-rs"
---

# JAFRON released its first-quarter performance, with a net profit attributable to the parent company of 189 million yuan, a year-on-year decrease of 33.71%

According to the Zhitong Finance APP, JAFRON (300529.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 548 million yuan, a year-on-year decrease of 26.40%. The net profit attributable to shareholders of the listed company was 189 million yuan, a year-on-year decrease of 33.71%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 184 million yuan, a year-on-year decrease of 32.15%

### Related Stocks

- [300529.CN](https://longbridge.com/en/quote/300529.CN.md)

## Related News & Research

- [11:00 ETCovationBio's Xatryx® Mass Production On Spec, to Debut First Non‑Food Bio‑Based Athletic Insole at NW Materials Show in the U.S.](https://longbridge.com/en/news/297804526.md)
- [Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here](https://longbridge.com/en/news/297670066.md)
- [PharmaEssentia’s Besremi receives FDA approval for ET](https://longbridge.com/en/news/297630746.md)
- [Egetis says tiratricol wins Japan orphan drug designation for MCT8 deficiency](https://longbridge.com/en/news/297469294.md)
- [06:05 ETKarmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer](https://longbridge.com/en/news/297497971.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**